Once-weekly treatment with Tirzepatide also led to superior glycemic control, measured using continuous glucose monitoring (CGM), compared to insulin degludec in participants with T2DM on metformin, with or without an SGLT2 inhibitor [46]. The gene discussed is INS; the disease is type 2 diabetes mellitus.